Teladoc Health shares fell about 24% after the telehealth company missed second-quarter revenue expectations and cut its guidance for the rest of the year.
Revenue came in at $606.9 million against roughly $615 million expected, a 4% decline from the same quarter a year earlier. The company then lowered full-year revenue guidance to a range of $2.36 billion to $2.45 billion, about 5% below its previous range at the midpoint and far below the $2.557 billion analysts had modelled.
The third-quarter outlook was worse still. Teladoc guided to between $569 million and $609 million against an analyst estimate of $641.9 million, a shortfall of more than 5% even at the top of the range.
BetterHelp is the problem
The decline is concentrated in one part of the business.
BetterHelp, the direct-to-consumer therapy platform, is now expected to shrink between 12.7% and 19% over the full year. That is not a slowdown in growth. It is a business contracting by up to a fifth.
BetterHelp was built on customers paying out of pocket, typically found through heavy digital advertising. That model works while acquisition costs stay below the lifetime value of a subscriber. It stops working when advertising becomes more expensive, when competitors enter, or when the customers who were willing to pay cash have already been reached.
The strategy shift is causing the shortfall
Teladoc is moving BetterHelp away from cash-paying customers and toward services covered by insurance. In principle that is the right direction. Insurance-covered therapy has a far larger addressable market and does not depend on persuading individuals to pay several hundred dollars a month themselves.
The difficulty is executional, and management named it. Chief executive Chuck Divita said demand from insurers is strong but provider capacity is limiting the ability to convert that demand into revenue.
That is a specific and unusual problem. The company has more customers available than it can serve, because it does not have enough licensed therapists to see them. Hiring clinicians takes time, credentialing with insurers takes longer, and neither can be accelerated with money alone.
So Teladoc is losing cash-pay revenue immediately while the insurance revenue meant to replace it arrives at the speed of recruitment.
Why the market reaction was so severe
A 24% fall on a 1.4% revenue miss looks disproportionate until the guidance is included.
Investors can absorb a weak quarter. What they price aggressively is a change in the trajectory. Cutting the full-year range by 5% at the midpoint, and guiding the next quarter more than 5% below expectations, tells the market that the shortfall is structural rather than seasonal.
This is the same mechanism that hit Carvana this week, which reported record results and fell 14% because its guidance came in below what analysts had assumed. As our report on that session noted, current performance sets the level and guidance sets the direction. Markets pay for direction.
What to watch
- Provider recruitment and credentialing rates, which determine how fast insurance-covered revenue can scale.
- BetterHelp cash-pay subscriber numbers, to see whether the decline is stabilising or accelerating.
- Customer acquisition cost, which drove the original model and explains why it stopped working.
- Whether the integrated care business, the part serving employers and health plans, holds up while BetterHelp shrinks.
Outlook
The transition Teladoc is attempting is defensible. Moving from consumer cash payments to insurance reimbursement is where most of American healthcare spending actually sits.
The problem is the order of events. The old revenue is falling now and the new revenue depends on hiring clinicians, which the company cannot do quickly. Guidance covering the rest of 2026 is effectively a statement about how many therapists Teladoc expects to bring onto its platform, which is a considerably less predictable variable than advertising spend.
Until provider capacity catches up with insurer demand, the revenue line will show the gap.
About the data: Figures are from Teladoc Health second-quarter 2026 results released on 29 July 2026, including quarterly revenue, the year-on-year change, the revised full-year 2026 revenue guidance range, the third-quarter guidance range and the expected decline in BetterHelp revenue. Analyst expectations referenced are consensus estimates compiled before the release. The comment attributed to the chief executive is from company commentary accompanying the results. The share price move is the decline recorded following the release.
Reader note
This article is general information, not personalized financial advice. Read our Financial Disclaimer.